INC Research Investor Presentation Jefferies 2015 Global Healthcare Conference
|
|
- Shanon Gray
- 6 years ago
- Views:
Transcription
1 INC Research Investor Presentation Jefferies 2015 Global Healthcare Conference June 1-4, 2015
2 Safe Harbor Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: fluctuations in our financial results; our ability to maintain or generate new business awards; our backlog not being indicative of future revenues and our ability to realize the anticipated future revenue reflected in our backlog; our ability to adequately price our contracts and not overrun cost estimates; our customer or therapeutic area concentration; international economic, political and other risks; our ability to increase our market share, grow our business and execute our growth strategies; our ability to perform services in accordance with contractual requirements, regulatory standards and ethical considerations; risks related to healthcare reform and other applicable regulations; our current and potential future indebtedness; and the other risk factors set forth from time to time in our Form 10- K for the year ended December 31, 2014, Form 10-Q for the quarter ended March 31, 2015 and other SEC filings, copies of which are available free of charge on our website at INC Research assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with GAAP, this presentation contains certain non-gaap financial measures, including Adjusted Net Service Revenue, Adjusted Income from Operations, Adjusted Operating Margin, Adjusted Net Income (including Adjusted Diluted Earnings per Share), EBITDA, and Adjusted EBITDA. A non-gaap financial measure is generally defined as a numerical measure of a company s financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP in the statements of income, balance sheets or statements of cash flow of the company. We define Adjusted Net Service Revenue as net service revenue excluding the impact of higher-than-normal change order activity that occurred during We define Adjusted Income from Operations as income from operations excluding the higher-than-normal change order activity and certain expenses such as management fees that terminated in connection with our initial public offering, acquisitionrelated amortization, restructuring costs, transaction expenses, non-cash stock compensation expense, contingent consideration related to acquisitions, and asset impairment charges. We define Adjusted Operating Margin as adjusted income from operations as a percent of adjusted net service revenue. We define Adjusted Net Income (including Adjusted Diluted Earnings per Share) as net income (including diluted earnings per share) excluding debt refinancing expenses, other income (expense) and the items excluded from adjusted income from operations mentioned previously. After giving effect to these items, we have also included an adjustment to our income tax rate to reflect the expected long-term income tax rate. EBITDA represents earnings before interest, taxes, depreciation and amortization. The Company defines Adjusted EBITDA as EBITDA excluding higher-than-normal change order activity and certain expenses such as management fees that terminated in connection with our initial public offering, restructuring costs, transaction expenses, non-cash stock compensation expense, contingent consideration related to acquisitions, asset impairment charges, debt refinancing expenses, results of and gains or losses from the sale of unconsolidated subsidiaries and other income/expense. The Company presents EBITDA because it believes it is a useful metric for investors as it is commonly used by investors, analysts and debt holders to measure our ability to service our debt obligations, fund capital expenditures and meet working capital requirements. Each of the non-gaap measures noted above are used by management and the Board to evaluate our core operating results as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business. Adjusted Net Service Revenue, Adjusted Income from Operations, Adjusted Operating Margin, and Adjusted Income (including Adjusted Diluted Earnings per Share) are used by management and the Board to assess our business, as well as by investors and analysts, to measure our performance. Adjusted EBITDA is also a helpful metric for management and investors to measure our ability to service our debt obligations. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Investors are encouraged to review the reconciliations of the non-gaap financial measures to their most directly comparable GAAP measures included in our Form 10-K for the year ended December 31, 2014, Form 8-K for the quarter ended March 31, 2015 and in the appendixes of our Q and Q earnings presentations which are available free of charge on our website at 2
3 INC Research at a Glance Business Overview Adjusted Net Service Revenue ($M) 2 A leading global clinical contract research organization ( CRO ) focused exclusively on Phase I to IV clinical development and related consulting services $ 652 $ 801 Not distracted by lower growth, lower margin non-clinical businesses Therapeutically-focused business model drives highly successful customer outcomes, strong top-line growth and above industry EBITDA margins Over 67% of backlog as of 3/31/15 in the largest and fastest growth therapeutic areas, including CNS, Oncology, and other complex diseases CRO industry analysts report that the most influential factor of choice for customers is therapeutic expertise Diversified customer base includes large, small, and mid-sized biopharmaceutical and medical device companies Top 5 customers account for 37% of net service revenue in 2014 and 36% of net service revenue in Q Top 10 customers account for 49% of net service revenue in both 2014 and Q Scale to deliver anywhere in the world Perform clinical trials in over 100 countries ~5,800 employees in more than 50 countries across six continents as of 3/31/15 $ 106 $ 145 $ 33 $ 51 % Q Q Margin 16.2% 18.1% 17.6% 24.2% $ 16 $ 45 $ 185 $ Q Q Adjusted EBITDA ($M) 1,2 Adjusted Net Income ($M) 1,2 $ 6 $ Q Q Adjusted EBITDA was favorably impacted by $6.2M of non-recurring items in Q The impact of these items on Adjusted Net Income was $4.0 million, which is net of tax of 36%. 2. During the second and third quarters of 2014, we experienced higher-than-normal change order activity estimated to be between $6.0M and $12.0M. Both Adjusted Net Service Revenue and Adjusted EBITDA have been adjusted by $9.0M in 2014 to remove the impact of this higher-than-normal change order activity. Adjusted Net Income, net of tax of 37%, has been adjusted by $5.7M. For a complete reconciliation of GAAP to Non-GAAP measures for current and historical periods, please refer to our Form 10-K for the year ended December 31, 2014, Form 8-K for the quarter ended March 31, 2015 and the appendixes of our Q and Q earnings presentations which are available free of charge on our website at 3
4 What Differentiates INC Research? Exclusively Focused on Phase I IV Clinical Development Therapeutically Focused Down to CRA Level (over 80% of CRAs Principally Focused on One Therapeutic Area) Strong Position in Largest, Fastest Growing Therapeutic Areas Highly Diversified Customer Base Outstanding Financial Growth Profile 4
5 Industry Trends and Growth Drivers Trends in Late-Stage Outsourcing ($B) INC s Market Industry Growth Drivers Continued prioritization of late-stage outsourcing in high-growth end markets Desire for therapeutic expertise, specifically in complex areas such as CNS and Oncology $ 76.9 $(9.9) $(11.8) $ 23.1 $ 35.8 Increasing need to access protocol-eligible patient populations for improved, actionable data Expanding commercial value of products through applications for regulatory approvals in multiple countries $(32.1) Growing drug development spend by biopharmaceutical companies as cost and complexity of development increase Drug Dev. Spend Pre- Clinical Dev. Non-CRO Indirect Fees In-House Clinical Dev. CRO Clinical Dev. Market (2014E) CRO Clinical Dev. Market (2020E) Biopharmaceutical focus on core competencies related to drug discovery and commercialization, driving continued use of full-service CROs for timely, accurate and complete data to aid decision making in clinical development Source: William Blair Equity Research (Oct 2014) 5
6 INC Research Key Investment Highlights 1 Deep and Long-Standing Expertise in the Largest and Fastest Growing Therapeutic Areas Clinical Development Focus and Innovative Operating Model Industry-Leading Principal Investigator and Clinical Research Site Relationships 2 Diversified, Loyal and Growing Customer Base Broad Global Reach with In-Depth Local Market Knowledge 3 Highly Experienced Management Team with a Deep-Rooted Culture of Quality and Innovation 4 Strong, Multi-Pronged Growth Strategy 5 Outstanding Financial Profile and Robust Momentum 6
7 1 Deep and Long-Standing Expertise in the Largest and Fastest Growing Therapeutic Areas INC s Backlog is Focused in High Growth Areas CNS, Oncology & Other Complex Diseases as a % of for Which Performance Exceeds Overall Industry Growth Growth 60% 1 67% 24% 26% 9% Total Phase III Drugs in Development INC Backlog as of 3/31/15 CRO Industy Net Service Revenue 4 (Overall) INC Net Service Revenue Growth (Overall) INC Net Service Revenue Growth (Complex Diseases) Increasing Trial Complexity Requires Deep Therapeutic Expertise 106 Total Procedures 2 in Clinical Trial Protocols Complexity has increased by 57% between 2000 and E&Y report, Beyond borders, Unlocking value (2014). 2. Clinical trial procedures include blood-work, routine exams, X-rays, etc. 3. Tufts CSDD presentation, Clinical Trial Complexity (2012). 4. William Blair Equity Research (Oct 2014). Complex trial design expertise is a significant competitive advantage for INC CRO industry analysts report that the most influential factor of choice for customers is therapeutic expertise CNS and oncology often require more complex testing protocols than other indications INC requires that oncology CRAs have oncologyspecific training and experience Over 80% of INC s CRAs are principally focused in one therapeutic area, and over 70% are solely focused in their area of expertise 7
8 1 Third Party Recognition of Industry-Leading Principal Investigator Site Relationships Top CRO to Work With among large global CROs in biannual CenterWatch Global Investigative Site Relationship Survey for a second straight time (2015 and 2013) #1 Top-three CRO on 4 of 5 attributes rated most important to study conduct success Professional medical staff in clinical operations Only CRO to rank consistently among Top 3 in all 7 CenterWatch surveys since 2007 Total Number of Attributes Ranked Top TOP 3 Professional, knowledgeable, welltrained monitors/cras 4 TOP 3 TOP 3 Ensures timely drug availability Easily accessible staff/ timely resolution Average % Good / Excellent Ratings Across Attributes INC Median 83% 80% CROs were evaluated against a total of 37 attributes INC ranked top 3 on 33 out of 37 attributes Source: CenterWatch 2015 Global Site Survey; more than 1,900 sites responded. 11 CROs evaluated, including top 5 by revenue 8
9 2 Diversified, Loyal and Growing Customer Base Diversified base of over 300 customers and performed work for 19 of the largest 20 biopharma companies, as ranked by sales, since the beginning of 2014 Added 58 new customers in 2014, with particularly strong growth among small to mid-sized biopharma companies Top five customers represented approximately 66 compounds in 40 indications across 167 active projects in 2014 Customer Profile Customer Loyalty Limited Customer Concentration 2014 Revenue 2014 New Business Awards Q Revenue Astellas 11% Large BioPharma 57% Small to Mid-Sized BioPharma 43% Repeat Customers 92% Rest of Top-10 13% Rest of Top-5 25% Top-5 = 36% Top-10 = 49% 2013 Revenue 2013 New Business Awards 2014 Revenue Otsuka 14% Large BioPharma 57% Small to Mid-Sized BioPharma 43% Repeat Customers 90% Rest of Top-10 12% Astellas 12% Rest of Top-5 11% Top-5 = 37% Top-10 = 49% 9
10 3 Highly Experienced Management Team with a Deep-Rooted Culture of Quality and Innovation Experienced senior management, each with over 20 years of relevant experience, is well-positioned to capitalize on attractive industry growth trends Jamie Macdonald Chief Executive Officer Alistair Macdonald President and Chief Operating Officer Michael Gibertini President Clinical Development and General Manager, CNS Greg Rush EVP & Chief Financial Officer v Chris Gaenzle Chief Administrative Officer and General Counsel Neil Ferguson EVP of Global Business Development v Innsight Medical Devices Caremark Jean Chitwood Senior VP of Corporate Strategy Therapeutic Business Heads Nicholas Kenny EVP Clinical Development and General Manager, Global Oncology Ian Braithwaite EVP Clinical Development and General Manager, General Medicine Sally Osmond EVP Clinical Development and General Manager, Cardiovascular & Endocrinology, Post Approval and Strategic Services Note: Logos in dotted boxes represent prior work experience. 10
11 4 INC s Strong, Multi-Pronged Growth Strategy Focus on Attractive, High-Growth Late-Stage Clinical Development Services Market Late stage CRO market estimated to grow 7-8% annually through Leverage INC s Expertise in Complex Clinical Trials Deep expertise in complex therapeutic areas positions INC to win new clinical trials in largest and fastest growth areas Capitalize on INC s Geographic Scale Significant presence across key markets and strong relationships with principal investigators and global sites Continuous Enhancement of Trusted Process Methodology to Deliver Superior Outcomes Strong alignment with key best-in-class technology providers improves operational efficiencies and reduces need for significant future investments, driving attractive returns Continue Identifying and Successfully Integrating Acquisitions to Augment Organic Growth Successfully integrated ten acquisitions since 2001; future focus is on smaller, tuck-in acquisitions Driving Human Capital Asset Base to Grow Existing Relationships Over 80% of CRAs principally focused in one therapeutic area and over 70% of CRAs solely focused in their area of expertise 1. Source: William Blair Equity Research (Oct 2014) 11
12 5 Strong Historical Financials Adjusted Net Service Revenue ($M) 2 Adjusted EBITDA ($M) 1,2 Adjusted Net Income ($M) 1,2 $ 579 $ 652 $ 801 $ 84 $ 106 $ 145 $ 45 $ 26 $ 185 $ 212 $ 33 $ 51 $ 45 $ 2 $ 16 $ 6 $ Q1 '14 Q1 ' Q1 '14 Q1 ' Q1 '14 Q1 '15 Net Service Revenue Drivers Driven by strength of new business awards and backlog position Therapeutic expertise and global reach resonating with customers Execution by experienced management team On a constant currency basis, net service revenue grew by 19.5% in Q Adjusted EBITDA Drivers Continued cost focus, leveraging global infrastructure particularly in SG&A Further synergies in consolidating facilities and information technology systems Utilization efficiency gains realized through Trusted Process Adjusted Net Income Drivers Continued strong net service revenue growth Cost initiatives under Adjusted EBITDA drivers Continued deleveraging resulted in annual interest expense reduction of -15% (-$9.2M) from 2012 to 2014 Refinancing from Term Loan B to Term Loan A expected to reduce interest expense by additional $4-5M in Adjusted EBITDA was favorably impacted by $6.2M of non-recurring items in Q The impact of these items on Adjusted Net Income was $4.0 million, which is net of tax of 36%. 2. During the second and third quarters of 2014, we experienced higher-than-normal change order activity estimated to be between $6.0M and $12.0M. Both Adjusted Net Service Revenue and Adjusted EBITDA have been adjusted by $9.0M in 2014 to remove the impact of this higher-than-normal change order activity. Adjusted Net Income, net of tax of 37%, has been adjusted by $5.7M. 3. Excludes a foreign currency headwind of approximately $9.1M in Q For a complete reconciliation of GAAP to Non-GAAP measures for current and historical periods, please refer to our Form 10-K for the year ended December 31, 2014, Form 8-K for the quarter ended March 31, 2015 and the appendixes of our Q and Q earnings presentations which are available free of charge on our website at 12
13 5 Industry Leading Margins with Sustainable Path to Continued Expansion Increasing Adjusted EBITDA Margin 14.6% 16.2% % 17.6% % Several identified and discrete margin expansion opportunities exist 21.3% Q Q Drivers of Incremental Margin Upside SG&A as a percentage of net service revenue projected to decline as a result of operating leverage Streamlining project management systems from 5 clinical trial management systems (CTMS) to primarily 1 Optimizing global footprint to achieve cost synergies from facility consolidation Continual process improvement to decrease time required / resources committed to specific trial components 25% reduction in time required for finalization of clinical monitoring trip reports 1. Adjusted EBITDA was favorably impacted by $6.2M of non-recurring items in Q (a favorable margin impact of approximately 295 basis points). Additionally, Q was favorably impacted by approximately 70 basis points due to foreign currency fluctuations. 2. During the second and third quarters of 2014, we experienced higher-than-normal change order activity estimated to be between $6.0M and $12.0M. Both Adjusted Net Service Revenue and Adjusted EBITDA have been adjusted by $9.0M in 2014 to remove the impact of this higher-than-normal change order activity (a negative margin impact of approximately 90 basis points). For a complete reconciliation of GAAP to Non-GAAP measures for current and historical periods, please refer to our Form 10-K for the year ended December 31, 2014, Form 8-K for the quarter ended March 31, 2015 and the appendixes of our Q and Q earnings presentations which are available free of charge on our website at 13
14 5 Strong Cash Flow and Leverage Profile $M Q Q Cash Flow from Operations $ 37.3 $ $ 31.2 $ 43.6 Less: Capital Expenditures Free Cash Flow Adjusted EBITDA $M 12/31/ /31/2014 3/31/2014 3/31/2015 Cash $ 97.0 $ $ $ Total Debt Net Debt Net Leverage x 2.1 x 4.0 x 1.6 x Note: Due to rounding of specific line items, line item figures may not sum to subtotals. These metrics do not reflect the potential impact of refinancing our existing debt, the potential share repurchase or the incremental $101.1 million in debt to be incurred to fund the share repurchase. 1. Free cash flow represents cash flow from operations less capital expenditures. 2. Total debt includes all outstanding indebtedness as of the end of the specified time period, prior to any related discount, plus any capital lease obligations. 3. Net leverage is calculated as Net Debt as of the date presented, divided by trailing twelve month Adjusted EBITDA of $105.5M for 12/31/13, $145.3M for 12/31/14, $120.1M for 3/31/14, and $163.9M for 3/31/15. For a complete reconciliation of GAAP to Non-GAAP measures for current and historical periods, please refer to our Form 10-K for the year ended December 31, 2014, Form 8-K for the quarter ended March 31, 2015 and the appendixes of our Q and Q earnings presentations which are available free of charge on our website at 14
15 5 High Quality Backlog Supports Long-Term Growth Backlog Roll Forward ($M) Q1 '14 Q2 '14 Q3 '14 Q4 '14 Q1 '15 Beginning Backlog $ 1,491 $ 1,594 $ 1,493 $ 1,506 $ 1,589 + Acquired Backlog Net Awards Revenue, as reported (185) (204) (208) (214) (212) + FX Adjustment 4 (1) (28) (19) (39) Ending Backlog $ 1,594 $ 1,493 $ 1,506 $ 1,589 $ 1,595 As of March 31, 2015 Backlog by Therapeutic Area Other Complex Diseases 12% Central Nervous System 34% Oncology 21% CNS, Oncology, & Other Complex Diseases = 67% of Backlog Backlog Coverage ($M) Backlog Burn Rate 2 RoY Backlog Revenue 1 $893 $765 $810 $807 $652 $577 15% 14% 13% 12% 14% 13% 12% 13% 14% 14% 13% 12% 11% 2013A 2014A 2015E 11% Backlog as of Coverage Ratio YoY Revenue Growth 3/31/ % 12.7% 3/31/ % 24.1% 3/31/ % 10.2% 10% Note: Due to rounding of specific line items, line item figures may not sum to subtotals. Financials and related key operating metrics have not been adjusted to exclude the $9.0M of higher-than-normal change order activity for full year revenue estimate represents the mid-point of the guidance issued on April 27, 2015 included in our Form 8-K for the quarter ended March 31, This guidance was as of April 27, 2015, and is not being hereby updated. 2. Backlog burn represents current quarter net revenue divided by previous quarter ending backlog. 15
16 5 Consistently Strong Net New Business Awards Growth Driving Book-to-Bill Historical Net New Business Awards ($M) Net Book-to-Bill $ $ x 1.2 x 1.2 x 1.2 x $ $ Q Six out of the last seven quarters have net book-to-bill of 1.2x or higher (ranging from 1.2x to 1.8x in those quarters) Book-to-bill for 2014 was 1.2x, particularly strong given revenue growth profile of over 20% for same period Net new business awards growth of 20.4% in 2013 and 16.7% in 2014, providing strong future revenue growth Net new business awards growth keeping pace with strong adjusted revenue growth of 12.7% in 2013 and 22.7% in 2014 Despite a large ~$132M customer cancellation in Q2 14 (related to drug profile and FDA discussions), customer remained a top-5 customer 16
17 5 Long-Term Financial Goals and Strategy Through continued growth, strategic focus, and financial discipline, we are targeting the following long-term financial growth and margin profile: Approximately 10-12% long-term revenue growth (above late-stage development market growth of 7-8%) Average long-term net book-to-bill ratio of ~1.2x Approximately 13-15% long-term Adjusted EBITDA growth Adjusted EBITDA margins consistently at or above 20% over the long term Gain efficiencies via global infrastructure, facility and IT systems consolidation; improve service delivery model through enhancements to the Trusted Process Approximately 20% long-term Adjusted Net Income growth Benefits from reduced interest costs and tax structure 17
INC Research Q4 & Full Year 2016 Financial Results. February 28, 2017
INC Research Q4 & Full Year 2016 Financial Results February 28, 2017 Forward Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the statements,
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Alistair Macdonald Chief Executive Officer January 8, 2019 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking
More informationBaird Global Healthcare Conference
Baird Global Healthcare Conference Jason Meggs Chief Financial Officer September 6, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationSyneos Health. Q4 and Full Year 2017 Financial Results. February 28, 2018
Syneos Health Q4 and Full Year 2017 Financial Results February 28, 2018 Forward-Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the
More informationSyneos Health. Q Financial Results. August 2, 2018
Syneos Health Q2 2018 Financial Results August 2, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements Except for historical information,
More informationINC Research/inVentiv Health Reports Third Quarter 2017 Results
Exhibit 99.1 FOR IMMEDIATE RELEASE INC Research/inVentiv Health Reports Third Quarter Results Highlights Net service revenue of 592.2 million and 1,102.4 million for the three and nine months ended, respectively.
More informationFourth Quarter 2015 Earnings Call February 11, 2016
Fourth Quarter 205 Earnings Call February, 206 Copyright 206 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the
More informationQ Financial Results. February 26, 2018
Q4 2017 Financial Results February 26, 2018 Forward Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationinventiv Health Supplemental Investor Presentation
inventiv Health Supplemental Investor Presentation May 10, 2017 Disclaimers Non-GAAP Financial Measures This presentation contains the non-gaap financial measures EBITDA and Adjusted EBITDA. EBITDA and
More informationJefferies Global Healthcare Conference
Jefferies Global Healthcare Conference June 7, 2012 2012 PAREXEL International Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationWILLIAM BLAIR GROWTH STOCK CONFERENCE JUNE 12, 2018 CHICAGO, IL
WILLIAM BLAIR GROWTH STOCK CONFERENCE JUNE 12, 2018 CHICAGO, IL FORWARD LOOKING STATEMENT AND USE OF ADJUSTED MEASURES This presentation contains forward-looking statements including but not limited to
More informationPAREXEL INTERNATIONAL
PAREXEL INTERNATIONAL Jefferies Healthcare Conference June 8, 2016 2015 PAREXEL INTERNATIONAL CORP. SAFE HARBOR This presentation contains forward-looking statements within the meaning of Section 27A of
More informationQ Earnings Call
Q3 2018 Earnings Call October 22, 2018 Copyright 2018 IQVIA. All rights reserved. Legal This presentation should be viewed in conjunction with IQVIA s Q3 2018 earnings call Safe Harbor Statement for Forward-Looking
More informationJEFFERIES GLOBAL HEALTHCARE CONFERENCE
JEFFERIES GLOBAL HEALTHCARE CONFERENCE November 20, 2014 2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. SAFE HARBOR This presentation contains forward-looking statements within the meaning of Section
More informationIQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationStericycle Investor Presentation Q NASDAQ: SRCL
Stericycle Investor Presentation Q3-2017 NASDAQ: SRCL Forward - Looking Statements Safe Harbor Statement: This press release may contain forward-looking statements that involve risks and uncertainties,
More informationNews Release. Investor Relations: Amy Glynn/Yaeni Kim, /5391 Media Relations: Anne Taylor Adams,
News Release Investor Relations: Amy Glynn/Yaeni Kim, +1 646 654 4931/5391 Media Relations: Anne Taylor Adams, +1 646 654 5759 NIELSEN REPORTS 3 rd QUARTER 2016 RESULTS New York, USA October 25, 2016 Nielsen
More informationIQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationIQVIA Reports Second-Quarter 2018 Results and Raises Full-Year 2018 Revenue and Profit Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationQ Earnings Call
Q1 2018 Earnings Call May 2, 2018 Copyright 2017 IQVIA. All rights reserved. Legal This presentation should be viewed in conjunction with IQVIA s Q1 2018 earnings call Safe Harbor Statement for Forward-Looking
More informationXylem Agrees to Acquire Sensus to Broaden Portfolio and Enhance Growth Platform AUGUST 15, 2016
1 Xylem Agrees to Acquire Sensus to Broaden Portfolio and Enhance Growth Platform AUGUST 15, 2016 Forward-Looking Statements This presentation contains information that may constitute forward-looking statements.
More informationQ Earnings Call
Q4 2017 Earnings Call February 14, 2018 Copyright 2017 IQVIA. All rights reserved. Legal This presentation should be viewed in conjunction with IQVIA s Q4 2017 earnings call Safe Harbor Statement for Forward-Looking
More informationJefferies 2016 Healthcare Conference CEO. June 7, 2016 NYSE: Q. Copyright 2016 Quintiles
Jefferies 2016 Healthcare Conference Tom Pike CEO June 7, 2016 Copyright 2016 Quintiles NYSE: Q Cautionary Statements Regarding Forward Looking Statements This communication contains forward-looking statements
More informationIQVIA Reports First-Quarter 2018 Results and Raises Full-Year 2018 Revenue Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationDave Carlucci Chairman and CEO IMS Health
Dave Carlucci Chairman and CEO IMS Health 1 March 11, 2009 Safe Harbor Certain statements we make today are forward-looking within the meaning of the US federal securities laws. These statements include,
More informationGardner Denver Reports Strong Third Quarter 2018 Results
Gardner Denver Reports Strong Third Quarter 2018 Results October 25, 2018 Revenues of $689 million increased 6% over the prior year Reported net income of $72 million compared to prior year of $28 million
More informationThe Manitowoc Company, Inc.
The Manitowoc Company, Inc. RBC CAPITAL MARKETS GLOBAL INDUSTRIALS CONFERENCE SEPTEMBER 5, 2018 LAS VEGAS, NV Dave Antoniuk, SVP & CFO Ion Warner, VP Marketing & IR Forward- Looking Statements Safe Harbor
More informationQuintilesIMS. Q Earnings Call. February 14, Copyright 2016 QuintilesIMS. All rights reserved.
QuintilesIMS Q4 2016 Earnings Call February 14, 2017 Copyright 2016 QuintilesIMS. All rights reserved. Legal This presentation should be viewed in conjunction with QuintilesIMS s Q4 2016 earnings call
More informationLOOKING statements. Forward
1 Forward LOOKING statements This presentation contains forward-looking statements regarding future events or the future financial performance of the Company that involve substantial risks and uncertainties.
More informationInvestor Overview Presentation. August 2018
Investor Overview Presentation August 2018 Forward-Looking Statements Statements about future results made in this presentation constitute forward-looking statements within the meaning of the Private Securities
More informationFirst-Quarter 2018 Earnings
First-Quarter 208 Earnings Baxter International Inc. April 26, 208 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results, business development
More informationAvnet Fiscal First Quarter 2019 Financial Results. Bill Amelio Chief Executive Officer
Avnet Fiscal First Quarter 2019 Financial Results Bill Amelio Chief Executive Officer Safe harbor statement This document contains certain forward-looking statements within the meaning of Section 27A of
More informationNews Release. Investor Relations: Sara Gubins, Media Relations: Anne Taylor Adams,
News Release Investor Relations: Sara Gubins, +1 646 654 8153 Media Relations: Anne Taylor Adams, +1 646 654 5759 NIELSEN REPORTS 4 th QUARTER AND FULL YEAR RESULTS New York, USA February 8, 2018 Nielsen
More informationCopyright 2018 CPI Card Group. Fourth Quarter & FY 2017 Earnings Conference Call March 12, 2018
Fourth Quarter & FY 2017 Earnings Conference Call March 12, 2018 Safe Harbor Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements
More informationRaymond James 37 th Annual Institutional Investors Conference. March 8, 2016
Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Forward-looking statements and Non-GAAP financial measures Forward-looking statements Certain statements included in this presentation,
More information2016 Financial Update and 2017 Outlook. Webcast Presentation December 13, 2016
2016 Financial Update and 2017 Outlook Webcast Presentation December 13, 2016 Safe Harbor Statement Note: All statements made herein that are not historical facts should be considered as forwardlooking
More informationWilliam Blair Growth Stock Conference. Eric Dey EVP & CFO
William Blair Growth Stock Conference Eric Dey EVP & CFO June 12, 2018 Safe Harbor Provision This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements
More informationON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS. (in millions, except per share data)
ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) Revenues $ 1,377.6 $ 1,377.5 $ 1,436.7 Cost of revenues (exclusive of amortization
More informationAngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results Company posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance Q4 net sales of
More informationON Semiconductor Reports Third Quarter 2018 Results
News Release Revenue of $1,541.7 million Gross margin of 38.7 percent GAAP operating margin of 15.7 percent and non-gaap operating margin of 17.8 percent Operating cash flow of $358.2 million and free
More informationQ Earnings Call. May 3, 2016
IMS Health Q1 2016 Earnings Call May 3, 2016 0 Legal This presentation should be viewed in conjunction with IMS Health s Q1 2016 earnings call Safe Harbor Statement This presentation ti includes forward-looking
More informationNCR Announces Fourth Quarter and Full Year 2018 Results
NCR Corporation Logo NCR Announces Fourth Quarter and Full Year 2018 Results February 7, 2019 ATLANTA--(BUSINESS WIRE)--Feb. 7, 2019-- NCR Corporation (NYSE: NCR) reported financial results today for the
More informationHill-Rom Fourth Quarter 2016 Financial Results. November 3, 2016
Hill-Rom Fourth Quarter 2016 Financial Results November 3, 2016 Forward Looking Statements Certain statements in this presentation contain forward-looking statements, within the meaning of the Private
More informationThird Quarter 2018 Earnings Call November 2, 2018
Third Quarter 2018 Earnings Call November 2, 2018 Forward-Looking Statements This supplemental information contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationQ4 AND FULL YEAR 2017 EARNINGS
Q4 AND FULL YEAR 2017 EARNINGS 2/14/2018 CONFERENCE CALL SAFE HARBOR FORWARD-LOOKING STATEMENTS Statements made in this presentation, including those related to revenues and net income for the first quarter
More information2018 Revenues Decreased 0.9%, or 0.7% on a Constant Currency Basis, in Line with Guidance
News Release Investor Relations: Sara Gubins, +1 646 654 8153 Media Relations: Laura Nelson, +1 203 563 2929 NIELSEN REPORTS 4 th QUARTER AND FULL YEAR 2018 RESULTS 2018 Revenues Decreased 0.9%, or 0.7%
More informationCross Country Healthcare acquires Advantage RN
Cross Country Healthcare acquires Advantage RN Forward Looking Statements This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future
More informationON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data)
UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) Revenue $ 1,455.9 $ 1,377.6 $ 1,338.0 $ 2,833.5 $ 2,774.7 Cost of revenue (exclusive of amortization shown below) 900.9
More informationQ EARNINGS 8/1/2018 CONFERENCE CALL. Copyright 2017 ARRIS Enterprises, LLC. All rights reserved
Q2 2018 EARNINGS 8/1/2018 CONFERENCE CALL Copyright 2017 ARRIS Enterprises, LLC. All rights reserved Safe Harbor FORWARD-LOOKING STATEMENTS Statements made in this presentation, including those related
More informationON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data)
UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) Revenue $ 1,503.1 $ 1,541.7 $ 1,377.5 $ 5,878.3 $ 5,543.1 Cost of revenue (exclusive of amortization shown below) 933.4
More informationFourth Quarter 2017 Earnings Call. February 16, 2018
Fourth Quarter 2017 Earnings Call February 16, 2018 Forward-Looking Statements This supplemental information contains forward-looking statements within the meaning of the Private Securities Litigation
More information36 th Annual J.P. Morgan Healthcare Conference
36 th Annual J.P. Morgan Healthcare Conference Alistair Macdonald Chief Executive Officer January 9, 2018 Forward-Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements Except for
More informationDriving Total Shareholder Return
ANALYST MEETING Driving Total Shareholder Return David Shedlarz Vice Chairman Agenda Total Shareholder Return (TSR) framework Key TSR drivers Business development Cost reduction Continuous improvement
More information/// The New Wabtec. February 25, 2019
The New Wabtec February 25, 2019 DISCLAIMER / FORWARD-LOOKING STATEMENTS Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section
More informationFIRST QUARTER 2019 EARNINGS CONFERENCE CALL FEBRUARY 28, 2019
FIRST QUARTER 2019 EARNINGS CONFERENCE CALL FEBRUARY 28, 2019 Safe harbor FORWARD-LOOKING STATEMENTS This presentation contains certain forward-looking information within the meaning of the Private Securities
More informationFirst Quarter 2018 Financial Results. January 26, 2018
First Quarter 2018 Financial Results January 26, 2018 This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included
More informationSecond Quarter Calendar Year 2018 Financial Results August 9, 2018
Second Quarter Calendar Year 2018 Financial Results August 9, 2018 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future
More informationMcKesson Corporation J.P. Morgan Healthcare Conference
McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer Forward-Looking Statements Some of the information in this presentation is not historical in
More informationIMS Health Reports Second-Quarter 2014 Results. DANBURY, CT, July 24, 2014 IMS Health Holdings, Inc. ( IMS Health ) (NYSE:IMS), a
News For Immediate Release Contacts: Tor Constantino Tom Kinsley Media Relations Investor Relations +1.484.567.6732 +1.203.448.4691 tconstantino@us.imshealth.com tkinsley@imshealth.com IMS Health Reports
More informationInvestor Presentation. Second Quarter 2018 NASDAQ: BECN BECN
Investor Presentation Second Quarter 2018 BECN 1 Disclosures Forward Looking Statements and Non-GAAP Measures This presentation contains forward-looking statements within the meaning of the Private Securities
More informationFOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018
FOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018 0 Agenda and Speakers Joe Woody Chief Executive Officer Halyard Outlook and Update on Divestiture 2018 Priorities Steve Voskuil Chief Financial Officer
More informationINVESTOR PRESENTATION. Fall 2017
INVESTOR PRESENTATION Fall 2017 DISCLAIMERS Forward-Looking Statements Statements in this document that are not statements of historical fact are forward-looking statements within the meaning of the safe
More informationPTC PREPARED REMARKS FOURTH QUARTER AND FULL YEAR FISCAL 2017 OCTOBER 25, 2017
PTC PREPARED REMARKS FOURTH QUARTER AND FULL YEAR FISCAL 2017 OCTOBER 25, 2017 Please refer to the Important Disclosures section of these prepared remarks for important information about our operating
More informationZimmer Biomet Reports Second Quarter 2016 Financial Results
July 28, 2016 Zimmer Biomet Reports Second Quarter 2016 Financial Results -- Net Sales of $1.934 billion represent an increase of 65.6% over the prior year period, and an increase of 4.5% on an adjusted
More informationDiplomat s Acquisition of LDI Integrated Pharmacy Services. Nov. 15, 2017
Diplomat s Acquisition of LDI Integrated Pharmacy Services Nov. 15, 2017 1 DISCLAIMERS NON-GAAP INFORMATION We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation
More informationStanding strong for payers and patients
Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE
More informationAcquisition of. June 20, 2016
Acquisition of June 20, 2016 Safe Harbor Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationINVESTOR PRESENTATION MARCH 2018
INVESTOR PRESENTATION MARCH 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking
More informationSecond Quarter 2018 Earnings Call August 3, 2018
Second Quarter 2018 Earnings Call August 3, 2018 Forward-Looking Statements This supplemental information contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationBaird s 2011 Business Solutions Conference
Baird s 2011 Business Solutions Conference Henrik Slipsager President and Chief Executive Officer David L. Farwell Senior Vice President Safe Harbor Our presentation today contains predictions, estimates
More information4Q16 Earnings Presentation
TUBULAR & ENERGY SERVICES CONSTRUCTION PRODUCTS RAIL PRODUCTS & SERVICES www.lbfoster.com 4Q16 Earnings Presentation March 2, 2017 Safe Harbor Statement This presentation and oral statements regarding
More informationTHIRD QUARTER FISCAL YEAR 2018 Earnings Conference Call & Presentation. August 7, 2018 at 9:00 a.m. CT (10:00 a.m. ET)
THIRD QUARTER FISCAL YEAR 2018 Earnings Conference Call & Presentation August 7, 2018 at 9:00 a.m. CT (10:00 a.m. ET) 1 Third Quarter Fiscal Year 2018 Welcome to Nexeo s Earnings Conference Call and Presentation
More informationMagellan Health. Cantor Fitzgerald Healthcare Conference September 26, 2017
Magellan Health Cantor Fitzgerald Healthcare Conference September 26, 2017 Cautionary Statement and Non-GAAP measures 2 This slide presentation and our accompanying oral comments include forward-looking
More informationFY 2019 First Quarter Earnings Call
FY 2019 First Quarter Earnings Call February 7, 2019 Improving the experience of a world in motion Important information Adient has made statements in this document that are forward-looking and, therefore,
More informationSecond Quarter 2013 Results. July 25, 2013
Second Quarter 2013 Results July 25, 2013 Disclaimer This presentation may contain forward-looking statements with respect to the financial condition, results of operation, plans, objectives, future performance
More informationWaters Corporation Management Presentation
Waters Corporation Management Presentation Chris O Connell Chairman & Chief Executive Officer January 2019 Cautionary Statements This presentation may contain forward-looking statements regarding future
More informationACQUISITION OF CARAUSTAR INDUSTRIES Significantly Enhances Margins and Free Cash Flow Strengthening its Leadership in Industrial Packaging
ACQUISITION OF CARAUSTAR INDUSTRIES Significantly Enhances Margins and Free Cash Flow Strengthening its Leadership in Industrial Packaging Safe harbor FORWARD-LOOKING STATEMENTS This presentation contains
More informationON Semiconductor Reports Fourth Quarter and 2018 Annual Results
ON Semiconductor Reports Fourth Quarter and Annual Results For the fourth quarter of, highlights include: Revenue of $1,503.1 million Gross margin of 37.9 percent GAAP operating margin of 14.8 percent
More informationAngioDynamics Reports Fiscal 2014 Second Quarter Financial Results
January 9, 2014 AngioDynamics Reports Fiscal 2014 Second Quarter Financial Results Net sales of $88.6 million GAAP income per share at break-even; Non-GAAP adjusted net income, excluding amortization,
More informationWaters Corporation Management Presentation. July 2018
Waters Corporation Management Presentation July 2018 Cautionary Statements This presentation may contain forward-looking statements regarding future results and events. For this purpose, any statements
More informationMicky Pant CEO, Yum China
Micky Pant CEO, Yum China Cautionary Language Regarding Forward-Looking Statements Forward-Looking Statements. Our presentation may contain forward-looking statements within the meaning of Section 27A
More informationFourth Quarter and Full Year 2018 Financial Review and Analysis
Fourth Quarter and Full Year 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same periods in the prior
More informationMylan: Q EARNINGS August 8, Q Earnings All Results are Unaudited
Mylan: Q2 2018 EARNINGS August 8, 2018 Q2 2018 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationON Semiconductor Reports Fourth Quarter and 2017 Annual Results
News Release ON Semiconductor Reports Fourth Quarter and 2017 Annual Results For the fourth quarter of 2017, highlights include: Revenue of $1,377.5 million GAAP gross margin of 37.3 percent and non-gaap
More informationNEW REVENUE ACCOUNTING STANDARD (ASC 606) February 7, 2018
NEW REVENUE ACCOUNTING STANDARD February 7, 2018 DISCLAIMERS Forward-Looking Statements Statements in this document that are not statements of historical fact are forward-looking statements within the
More informationTo Acquire. Creating the first and only global, comprehensive virtual healthcare delivery platform. June 19, 2017
To Acquire Creating the first and only global, comprehensive virtual healthcare delivery platform June 19, 2017 1 Today s Presenters Jason Gorevic President & CEO Mark Hirschhorn COO & CFO Peter McClennen
More information2018 Outlook. Webcast Presentation December 13, 2017
2018 Outlook Webcast Presentation December 13, 2017 Safe Harbor Statement All statements made herein that are not historical facts should be considered as forward-looking statements within the meaning
More informationJ.P. MORGAN HEALTHCARE CONFERENCE. Joe Woody Chief Executive Officer
J.P. MORGAN HEALTHCARE CONFERENCE Joe Woody Chief Executive Officer 0 OVERVIEW FORWARD-LOOKING INFORMATION Certain matters in this presentation and webcast, including our outlook, expectations and planning
More informationOur Transformation Continues. March 21, 2018
Our Transformation Continues March 21, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation, we make
More informationCapturing the Opportunity
Capturing the Opportunity JANUARY 2018 BETHANY DIPLOMAT PATIENT Copyright 2018 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. 1 SPECIALTY DRUGS
More informationInvestment Community Conference Call
DieboldNixdorf.com Investment Community Conference Call Third Quarter, 2018 Earnings October 31, 2018 Use of non-gaap Financial Information To supplement our condensed consolidated financial statements
More information2018 SECOND QUARTER FINANCIAL RESULTS
2018 SECOND QUARTER FINANCIAL RESULTS July 30, 2018 0 SAFE HARBOR STATEMENT The 2018 second quarter news release, conference call webcast, and the following slides contain forward-looking statements. The
More informationAngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results
AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results July 11, 2018 Fiscal 2018 Fourth Quarter Highlights Net sales of $88.3 million, an increase of 1.6% year over year Gross
More informationMylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
November 6, Mylan Reports Third Quarter Results and Updates Guidance HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results
More informationFourth Quarter Fiscal Year 2017
Fourth Quarter Fiscal Year 2017 October 25, 2017 J. Michael Bruff Vice President Investor Relations Mike.Bruff@Varian.com This presentation is intended exclusively for investors. It is not intended for
More informationQ Investors Presentation
Q2 2017 Investors Presentation Forward Looking Statements and Non-GAAP Measures This presentation contains information about management's view of the Company's future expectations, plans and prospects
More informationUnsaved Document / 9/18/2010 / 13:49. Proposed Acquisition of GAIN Capital Holdings, Inc. April 9, 2013
Unsaved Document / 9/18/2010 / 13:49 Proposed Acquisition of GAIN Capital Holdings, Inc. April 9, 2013 Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A
More informationPTC SECOND QUARTER FISCAL 2017 PREPARED REMARKS APRIL 19, 2017
PTC SECOND QUARTER FISCAL 2017 PREPARED REMARKS APRIL 19, 2017 Please refer to the Important Disclosures section of these prepared remarks for important information about our operating metrics (including
More information